Welcome to our dedicated page for XOMA Royalty news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty stock.
XOMA Royalty Corporation operates as a biotechnology royalty aggregator that acquires rights to potential milestone and royalty payments tied to therapeutic candidates licensed to pharmaceutical and biotechnology companies. Its updates commonly address portfolio additions, royalty-sharing transactions, commercial and development-stage assets, clinical and regulatory disclosures from underlying programs, and cash receipts from royalties and milestones.
Company news also covers financial results, preferred stock dividends on its Series A and Series B cumulative preferred securities, completed acquisitions that expand the royalty portfolio, and executive or governance changes. Named portfolio assets include VABYSMO, OJEMDA, MIPLYFFA, XACIATO, IXINITY, DARE to PLAY, DSUVIA, and development-stage assets such as mezagitamab.
XOMA Corporation announced that CEO Jim Neal will present at two investor conferences: the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 2:00 PM ET, and the Cantor Fitzgerald Virtual Global Healthcare Conference on September 15, 2020, at 4:00 PM ET.
Webcasts will be available on XOMA's investor relations website, with replays accessible for 90 days post-event. XOMA's portfolio encompasses various licensed programs in biotechnology, focusing on antibody therapeutics. The company emphasizes that all assets are still investigational and highlights potential risks in its forward-looking statements.
XOMA Corporation (Nasdaq: XOMA) reported its second quarter 2020 results, showcasing total revenues of $0.4 million, down from $1.0 million in Q2 2019. The net loss decreased to $3.5 million from $4.1 million year-over-year. Research and development expenses dropped to $0.04 million, while general and administrative expenses fell to $3.6 million. As of June 30, 2020, the company's cash and cash equivalents stood at $49.5 million, down from $56.7 million at the end of 2019, but management believes this is sufficient for multiple years of operation.
XOMA Corporation (NASDAQ: XOMA) has announced that CEO Jim Neal will present a business update at the Wedbush PacGrow Virtual Healthcare Conference on August 12, 2020, at 3:30 PM ET. The presentation will be live-streamed and accessible through the investor relations section of XOMA's website. An archived version will be available for 90 days post-event. XOMA focuses on licensing programs in biotechnology and pharmaceuticals, aiming to create value through milestone and royalty proceeds from partnered developments.
XOMA Corporation (NASDAQ: XOMA) has appointed Natasha A. Hernday to its Board of Directors. Hernday brings 20 years of corporate development experience, previously serving at Seattle Genetics and Amgen. CEO Jim Neal expressed confidence that Hernday's expertise in asset licensing and partnerships will enhance XOMA's royalty aggregator business model. Hernday is expected to play a pivotal role in advancing the company's strategy focused on human health breakthroughs through royalty aggregation.
XOMA Corporation (Nasdaq: XOMA) has been officially included in the Russell 2000® and Russell 3000® indexes as of June 26, 2020. This inclusion is expected to enhance the Company's visibility among investors and potentially expand its shareholder base, according to CEO Jim Neal. The Russell 3000® Index tracks the largest 3,000 U.S. stocks, while the Russell 2000® specifically focuses on small-cap stocks, influencing many investment strategies and index funds.